3-(3-Ethyl-1,2,4-oxadiazol-5-yl)quinuclidine Hydrogen Oxalate | 123837-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: 3-(3-Ethyl-1,2,4-oxadiazol-5-yl)quinuclidine Hydrogen Oxalate
• 英文别名: 5-(1-azabicyclo[2.2.2]octan-3-yl)-3-ethyl-1,2,4-oxadiazole;oxalic acid
• CAS: 123837-03-6
• 化学式: C₂H₂O₄*C₁₁H₁₇N₃O
• 分子量: 297.311
• InChiKey: IMQRAYZHGJQXNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-氮杂双环[2.2.2]辛烷-3-羧酸甲酯 、 N-羟基丙酸脒 生成 3-(3-Ethyl-1,2,4-oxadiazol-5-yl)quinuclidine Hydrogen Oxalate
  参考文献：
  名称：

  SAUNDER, JOHN;CASSIDY, MARK;FREEDMAN, STEPHEN B.;HARLEY, ELIZABETH A.;IVE+, J. MED. CHEM., 33,(1990) N, C. 1128-1138

  摘要：

  DOI：

文献信息

• Substituted oxadiazoles and thiadiazoles for use in the treatment of
  申请人：Merck Sharp and Dohme Ltd.

  公开号：US05134146A1

  公开（公告）日：1992-07-28

  The use of compounds for formula (I): ##STR1## or a salt or prodrug thereof; wherein one of X, Y, or Z is an oxygen or sulphur atom and the other two are nitrogen atoms, and the dotted circle represents two double bonds thus forming a 1,3,4-oxadiazole, 1,2,4-oxadiazole, 1,3,4-thiadiazole or 1,2,4-thiadiazole nucleus; R.sup.1 represents a non-aromatic azacyclic or azabicyclic ring system selected from ##STR2## wherein the broken line represents an optional chemical bond; the substituents R.sup.3 and R.sup.4 may be present at any position, including the point of attachment to the oxa- or thia-diazole ring, and independently represent hydrogen, C.sub.1-4 alkyl, halo, C.sub.1-4 alkoxy, hydroxy or carboxy, or R.sup.3 and R.sup.4 together represent carbonyl; the group R.sup.5 represents hydrogen or C.sub.1-4 alkyl; and R.sup.2 represents hydrogen, C.sub.1-8 hydrogen, C.sub.1-8 alkyl optionally substituted by hydroxy or fluoro, C.sub.2-8 alkenyl, OR.sup.7, SR.sup.7, NR.sup.7 R.sup.8, CN, CO.sub.2 R.sup.7, CONR.sup.7 R.sup.8 OR NHCONHR.sup.9 where R.sup.9 is C.sub.1-4 alkyl; wherein R.sup.7 and R.sup.8 independently represent hydrogen or saturated or unsaturated C.sub.1-4 alkyl provided that, when R.sup.7 and R.sup.8 in NR.sup.7 R.sup.8 are both hydrogen, at least one of R.sup.3 and R.sup.4 is C.sub.1-4 alkyl, in the treatment of glaucoma, novel compounds having such use, formulations containing them and their synthesis.

  化合物用于公式（I）：##STR1##或其盐或前药；其中X、Y或Z中的一个是氧或硫原子，另外两个是氮原子，虚线圆圈表示两个双键，从而形成1,3,4-噁二唑，1,2,4-噁二唑，1,3,4-噻二唑或1,2,4-噻二唑核；R.sup.1表示从##STR2##中选择的非芳香族氮杂环或氮杂双环环系；其中断线表示可选的化学键；取代基R.sup.3和R.sup.4可以出现在任何位置，包括连接到氧杂或硫杂噻唑环的位置，并且独立地表示氢，C.sub.1-4烷基，卤素，C.sub.1-4烷氧基，羟基或羧基，或R.sup.3和R.sup.4一起表示羰基；基团R.sup.5表示氢或C.sub.1-4烷基；R.sup.2表示氢，C.sub.1-8氢，C.sub.1-8烷基（可选地被羟基或氟取代），C.sub.2-8烯基，OR.sup.7，SR.sup.7，NR.sup.7R.sup.8，CN，CO.sub.2R.sup.7，CONR.sup.7R.sup.8或NHCONHR.sup.9，其中R.sup.9是C.sub.1-4烷基；其中R.sup.7和R.sup.8独立地表示氢或饱和或不饱和的C.sub.1-4烷基，只要在NR.sup.7R.sup.8中R.sup.7和R.sup.8都是氢时，R.sup.3和R.sup.4中至少有一个是C.sub.1-4烷基，在青光眼的治疗中使用这种新化合物，含有它们的制剂及其合成。
• Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0459568A2

  公开（公告）日：1991-12-04

  The use of compounds for formula (I): or a salt or prodrug thereof; wherein one of X, Y, or Z is an oxygen or sulphur atom and the other two are nitrogen atoms, and the dotted circle represents two double bonds thus forming a 1,3,4-oxadiazole, 1,2,4-oxadiazole, 1,3,4-thiadiazole or 1,2,4-thiadiazole nucleus;    R¹ represents a non-aromatic azacyclic or azabicyclic ring system selected from wherein the broken line represents an optional chemical bond;    the substituents R³ and R⁴ may be present at any position, including the point of attachment to the oxa- or thia-diazole ring, and independently represent hydrogen, C₁₋₄ alkyl, halo, C₁₋₄ alkoxy, hydroxy or carboxy, or R³ and R⁴ together represent carbonyl;    the group R⁵ represents hydrogen or C₁₋₄ alkyl; and    R² represents hydrogen, C₁₋₈ alkyl optionally substituted by hydroxy or fluoro, C₂₋₈ alkenyl, OR⁷, SR⁷, NR⁷R⁸, CN, CO₂R⁷, CONR⁷R⁸ OR NHCONHR⁹ where R⁹ is C₁₋₄ alkyl; wherein R⁷ and R⁸ independently represent hydrogen or saturated or unsaturated C₁₋₄ alkyl provided that, when R⁷ and R⁸ in NR⁷R⁸ are both hydrogen, at least one of R³ and R⁴ is C₁₋₄ alkyl, in the treatment of glaucoma, novel compounds having such use, formulations containing them and their synthesis.

  式(I)化合物的用途： 或其盐或原药；其中 X、Y 或 Z 中的一个是氧原子或硫原子，另外两个是氮原子，虚线圆圈代表两个双键，从而形成 1,3,4-噁二唑、1,2,4-噁二唑、1,3,4-噻二唑或 1,2,4-噻二唑核； R¹ 代表非芳氮杂环或氮杂环环系，选自 其中断线代表可选的化学键； 取代基 R³ 和 R⁴ 可存在于任何位置，包括与氧杂或硫杂二唑环的连接点，并独立地代表氢、C₁₋₄ 烷基、卤代、C₁₋₄ 烷氧基、羟基或羧基，或 R³ 和 R⁴ 共同代表羰基； 基团 R⁵ 代表氢或 C₁₋₄ 烷基；以及 R² 代表氢、任选被羟基或氟取代的 C₁₋₈ 烷基、C₂₋₈ 烯基、OR⁷、SR⁷、NR⁷R⁸、CN、CO₂R⁷、CONR⁷R⁸ OR NHCONHR⁹，其中 R⁹ 是 C₁₋₄ 烷基；其中 R⁷ 和 R⁸ 独立地代表氢或饱和或不饱和 C₁₋₄ 烷基，但当 NR⁷R⁸ 中的 R⁷ 和 R⁸ 都是氢时，R³ 和 R⁴ 中至少有一个是 C₁₋₄ 烷基、 用于治疗青光眼的新型化合物、含有这些化合物的制剂及其合成。
• US5134146A
  申请人：——

  公开号：US5134146A

  公开（公告）日：1992-07-28